JY
CGEM icon

Jeff Yass’s Cullinan Oncology CGEM Stock Holding History

Jeff Yass’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
86,600
-56,600
-40% -$840K ﹤0.01% 7039
2026
Q1 		$2.03M Sell
143,200
-63,200
-31% -$812K ﹤0.01% 6142
2025
Q4 		$2.14M Buy
206,400
+195,700
+1,829% +$1.77M ﹤0.01% 5521
2025
Q3 		$63.5K Buy
10,700
+100
+0.9% +$732 ﹤0.01% 11776
2025
Q2 		$79.8K Sell
10,600
-400
-4% -$3.21K ﹤0.01% 11909
2025
Q1 		$83.3K Sell
11,000
-8,500
-44% -$81.6K ﹤0.01% 11652
2024
Q4 		$238K Buy
19,500
+7,300
+60% +$105K ﹤0.01% 10334
2024
Q3 		$204K Sell
12,200
-30,900
-72% -$548K ﹤0.01% 10434
2024
Q2 		$752K Buy
+43,100
New +$918K ﹤0.01% 7252
2022
Q4 		– Sell
-12,400
Closed -$159K – 12512
2022
Q3 		$159K Buy
+12,400
New +$167K ﹤0.01% 11154

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jeff Yass's CGEM Position: Q2 2026 in Review

Jeff Yass reduced its Cullinan Oncology (CGEM) stake by 45% in Q2 2026, selling an estimated $316K and leaving 26,090 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #10037.

Jeff Yass first reported a position in CGEM in Q4 2021 and has held it in 17 quarters since. The position peaked at $978K in Q2 2025. 182 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Jeff Yass held 26,090 shares of Cullinan Oncology worth $475K as of Q2 2026.
  • Jeff Yass sold 21,287 Cullinan Oncology shares in Q2 2026, an estimated $316K.
  • Cullinan Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10037 holding.
  • Jeff Yass first reported a position in Cullinan Oncology in Q4 2021 and has held it in 17 quarters since.
  • Jeff Yass's Cullinan Oncology position peaked at $978K in Q2 2025.
  • 182 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.